Choline and Cardiometabolic Health
Choline and Cardiometabolic Health
NCT ID: NCT04764162 Phase: NA Status: COMPLETED Enrollment: 14 Completion: 2023-11-21
Conditions
Cardiovascular Risk Factor
Interventions
Choline, Placebo
Summary
Trimethylamine-N-oxide (TMAO), a metabolite produced by gut microbial metabolism of dietary choline, has recently been causally linked to atherosclerosis in animal models and has been shown to be predictive of cardiovascular disease (CVD) risk in some but not all cohort studies. The relevance of observations in animals to humans is unclear and little information is available on the mechanisms linking TMAO to increased CVD risk. Vascular dysfunction plays a critical role in the initiation and progression of atherothrombotic disease. Whether TMAO impairs vascular function in humans is not known. The purpose of this study is to determine if short term supplementation of dietary choline, which increases TMAO, affects CVD risk factors, such as glucose homeostasis and vascular function.
Primary Outcome
Change From Baseline in Insulin Sensitivity at 4 Weeks